ISRCTN14138956CompletedPhase 1
A phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- niversity of Oxford
- Enrollment
- 12
Study Overview
Brief Summary
2016 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/27619800 protocol 2018 Abstract results in https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.TPS536 abstract 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33217498/ results (added 29/09/2021)
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Current participant inclusion criteria as of 10/05/2018:
- •1. Borderline resectable localised tumour of the pancreatic head/uncinate process/body as per NCCN Guidelines (tumours of the tail of pancreas are not eligible for inclusion) or operable tumour in contact with or operable tumour in contact with, as defined by CT +/MRI +/PET criteria within 28+/7 days prior to trial entry de novo or following chemotherapy.
- •2. Histologically proven pancreatic ductal adenocarcinoma or cytological proven pancreatic malignancy
- •3. Able to undergo biliary drainage using a stent
- •4. Deemed fit and suitable for surgical resection
- •5. No overt metastases or uncertain status with investigations suspicious of possible metastatic disease (e.g. small equivocal pulmonary nodule(s)).
- •6. Male or female, Age = 16 years
- •7. Life expectancy of at least 6 months
- •7. ECOG performance status 0-1
- •8. The patient is willing and able to comply with the protocol for the duration of the study, and scheduled followup visits and examinations
- •9. Written (signed and dated) informed consent and be capable of cooperating with protocol
- •10. Haematological and biochemical indices within given ranges
- •Previous participant inclusion criteria:
- •1. Borderline resectable localised tumour of the pancreatic head/uncinate process/body as per NCCN Guidelines (tumours of the tail of pancreas are not eligible for inclusion) as defined by CT +/MRI +/PET criteria within 28+/7 days prior to trial entry
- •2. Histologically proven pancreatic ductal adenocarcinoma or cytological proven pancreatic malignancy
- •3. Able to undergo biliary drainage using a stent
- •4. Deemed fit and suitable for surgical resection
- •5. Male or female, Age = 16 years
- •6. Life expectancy of at least 6 months
- •7. ECOG performance status 0-1
- •8. The patient is willing and able to comply with the protocol for the duration of the study, and scheduled followup visits and examinations
- •9. Written (signed and dated) informed consent and be capable of cooperating with protocol
- •10. Haematological and biochemical indices within given ranges
Exclusion Criteria
- •Current participant exclusion criteria as of 10/05/2018:
- •1. Definite metastatic disease or local disease that cannot be encompassed in the SBRT field
- •2. History of previous or concurrent malignancy diagnoses for which the expected prognosis is likely to be worse than that of the current diagnosis of pancreatic cancer (excludes for example: e.g. localised prostate cancer, early colorectal cancer, early breast cancer, curatively-treated basal cell carcinoma of skin, carcinoma in situ of cervix; curatively treated cancer of other sites who are recurrence free for >3 years)
- •3. Serious medical or psychological condition precluding trial intervention
- •4. Previous upper abdominal or chest wall radiotherapy
- •5. Pregnancy. Pregnant or breastfeeding women or women of childbearing potential unless effective methods of contraception are used.
- •6. Any other psychological, social or medical condition, physical examination finding or laboratory abnormality that the Investigator considers makes the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of the trial results.
- •Previous participant exclusion criteria:
- •1. Distant metastatic disease or local disease that cannot be encompassed in the SBRT field
- •2. History of previous or concurrent malignancy diagnoses (except curatively-treated basal cell carcinoma of skin, carcinoma in situ of cervix; curatively treated cancer of other sites who are recurrence free for = 3 years)
- •3. Serious medical or psychological condition precluding neoadjuvant treatment and surgical resection
- •4. Previous upper abdominal or chest wall radiotherapy
- •5. Pregnancy. Pregnant or breastfeeding women or women of childbearing potential unless effective methods of contraception are used
- •6. Any other psychological, social or medical condition, physical examination finding or laboratory abnormality that the Investigator considers makes the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of the trial results.
Investigators
Similar Trials
Unknown
Phase 2
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderUrinary Bladder CancerNCT03529890Technical University of Munich33
Recruiting
Not Applicable
Clinical Trial for Preoperative High Intensity Interval Training (HIT) Prior to Oncological EsophagectomyC15.1Thoracic part of oesophagusDRKS00024938niversitätsklinikum Mannheim20
Completed
Not Applicable
Pre-operative oral supplementation in colorectal cancer patientsMalignant neoplasm of colonCancerColorectal cancerISRCTN02466810niversity of Manchester (UK)126
Recruiting
Phase 1
Proton or Photon RT for Retroperitoneal SarcomasRetroperitoneal SarcomaNCT01659203Massachusetts General Hospital80
Completed
Not Applicable
A multicentre pilot study to assess the feasibility of a future randomised controlled trial to investigate whether carrying out invasive bladder function tests in women about to undergo operations for stress incontinence alters the outcome of their surgeryStress urinary incontinence in womenUrological and Genital DiseasesOther disorders of urinary systemISRCTN71327395ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)120